Phase 2 N=42 Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Invasive Breast Cancer
Primary: Pathologic Complete Response (PCR) Rate — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Chronic Lymphocytic Leukemia · Leukemia
Primary: Best Response — 20; 3; 3 Participants
Phase 2 N=9 Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Event (AE) and, Serious Adverse Event (SAE) in Part A — 5; 1 Participants
Phase 2 N=50 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Estrogen Receptor-negative Breast Cancer · Estrogen Receptor-positive Breast Cancer · Inflammatory Breast Cancer
Primary: Event-free Survival — 11; 9 Participants
Phase 2 N=9 Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Weight — 0.70 lbs
Phase 2 N=360 Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Heart Failure
Primary: 96 Hour Change in NT-proBNP — -0.58; -0.61 log pg/ml — p=0.5688
Phase 2 N=20 Study of Leptin for the Treatment of Hypothalamic Amenorrhea
Amenorrhea
Primary: the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks…
Phase 2 N=50 Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
Cardiac Arrest
Primary: Time to Shock Reversal — 55; 49 hours
Phase 2 N=55 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Donor Engraftment (Chimerism) — 34 Participants
Phase 2 N=16 Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH
Endocrine Disease · Adrenal Insufficiency · Congenital Adrenal Hyperplasia
Primary: Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia — 601.213 nmol/L
Phase 2 N=10 Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers
Mood Disorder · Anxiety Disorders
Primary: Levels of NPY in CSF — 329.4; 351.0 pg/mL
Phase 2 N=136 Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
Alcoholism
Primary: Percent Heavy Drinking Days During Active Treatment Phase — 16.75; 24.28; 20.51; 21.78 days
Phase 2 N=28 Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Hematological Malignancy
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants
Phase 2 N=36 Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Refractory Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: Overall Survival — 9 Participants
Phase 2 N=20 Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
Colorectal Cancer
Primary: Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab. — 0; 9; 10 Participants